Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances,
such as radioactive iodine, to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody after
radiation therapy in treating patients with newly diagnosed primary brain tumors that can be
surgically resected.